MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03489nam a2200229Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
NULRC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250520100712.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250520s9999 xx 000 0 und d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780080466170 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
NULRC |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RM 301.25 .R93 2008 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rydzewski, Robert M. |
| Relator term |
author |
| 245 #0 - TITLE STATEMENT |
|---|
| Title |
Real world drug discovery : |
| Remainder of title |
a chemist's guide to biotech and pharmaceutical research / |
| Statement of responsibility, etc. |
Robert M. Rydzewski |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Amsterdam : |
| Name of publisher, distributor, etc. |
Elsevier Science, |
| Date of publication, distribution, etc. |
c2008 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xvii, 515 pages : |
| Other physical details |
color illustrations ; |
| Dimensions |
26 cm. |
| 365 ## - TRADE PRICE |
|---|
| Price amount |
USD75.04 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
1 The Drug Discovery Business to Date -- 2 The Drug Discovery Business to Come -- 3 Industrial Considerations -- 4 How Things Get Done: The Project Team -- 5 Project Considerations -- 6 Hit Generation -- 7 Turning Hits into Drugs -- 8 Initial Properties -- 9 ADME and PK Properties -- 10 Toxicity-Related Properties -- 11 A Career in Drug Discovery. The drug discovery business to date -- The drug discovery business to come -- Industrial considerations -- how things get done : the project team -- Project considerations -- Hit generation -- Turning hits into drugs -- Initial properties -- ADME and PK properties -- Toxicity related properties -- A career in drug discovery research |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Drug discovery increasingly requires a common understanding by researchers of the many and diverse factors that go into the making of new medicines. The scientist entering the field will immediately face important issues for which his education may not have prepared him: project teams, patent law, consultants, target product profiles, industry trends, Gantt charts, target validation, pharmacokinetics, proteomics, phenotype assays, biomarkers, and many other unfamiliar topics for which a basic understanding must somehow be obtained. Even the more experienced scientist can find it frustratingly difficult to get an overview of the many factors involved in modern drug discovery and often only after years of exploring does a whole and integrated picture emerge in the mind of the researcher. Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research presents this kind of map of the landscape of drug discovery. In a single, readable volume it outlines processes and explains essential concepts and terms for the recent science graduate wondering what to expect in pharma or biotech, the medicinal chemist seeking a broader and more timely understanding of the industry, or the contractor or collaborator whose understanding of the commercial drug discovery process could increase the value of his contribution to it. Key Features: - Interviews with well-known experts in many of the fields involved, giving insightful comments from authorities on many of the sub-disciplines important to cutting edge drug discovery. - Helpful suggestions gleaned from years of experience in biotech and pharma, which represents a repository drug discovery "lore" not previously available in any book. - "Periodic Table of Drugs" listing current top-selling drugs arranged by target and laid out so that structural similarities and differences are plain and clear, with regular updates available at the book's website. - Extensive use of diagrams to illustrate concepts like biotech startup models, preteomic profiling for target identification, Gantt charts for project planning, etc |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
DRUG DESIGN |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Books |
